Home LiteratureArticle Details
PMID: 8398710 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Expression of topoisomerase II alpha and beta in an adenocarcinoma cell line carrying amplified topoisomerase II alpha and retinoic acid receptor alpha genes.

British journal of cancer ·Vol. 68 ·No. 4 ·1993-10-00 ·Pages 793-800

Coutts J, Plumb JA, Brown R, Keith WN

Abstract

Human topoisomerase II enzymes are targets for a number of widely used anticancer agents. We have analysed a lung adenocarcinoma cell line CALU3, which has co-amplified topoisomerase II alpha and ERBB2 sequences, for the structure of the amplicon and for expression of both topoisomerase II alpha and beta. The region of chromosome 17q amplified in CALU3 also includes the retinoic acid receptor alpha locus and is therefore similar to the amplicon observed in breast cancers carrying amplified topoisomerase II alpha and retinoic acid receptor sequences. The use of fluorescence in situ hybridisation localises the amplified topoisomerase II alpha sequences to a cluster on one chromosome with single copies localised to others. CALU3 express high levels of topoisomerase II alpha is determined by Western blot, immunofluorescence and enzyme activity. The enzyme activity extracted from CALU3 is sensitive to inhibition by the topoisomerase II poison etoposide. Topoisomerase II beta expression was observed in three lung cancer cell lines including CALU3 and was confined to the nucleoli. Thus, the CALU3 cell line is an ideal model to study the amplification and expression of topoisomerase II alpha in adenocarcinomas.

MeSH Terms
Blotting, Western Carcinoma, Non-Small-Cell Lung/enzymology DNA Topoisomerases, Type II/analysis,genetics Gene Amplification Humans In Situ Hybridization, Fluorescence Isoenzymes/analysis Lung Neoplasms/enzymology Tumor Cells, Cultured
Chemicals
Isoenzymes DNA Topoisomerases, Type II
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Coutts J
CRC Department of Medical Oncology, Beatson Laboratories, Bearsden, Glasgow, UK.
Plumb J A
Brown R
Keith W N
References (30)
30 references, click to expand
  1. Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization.
    Proc Natl Acad Sci U S A. 1986 May;83(9):2934-8 PMID: 3458254
  2. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy.
    Cancer Res. 1991 Nov 1;51(21):5915-20 PMID: 1682037
  3. Circumvention of drug resistance in human non-small cell lung cancer in vitro by verapamil.
    Br J Cancer. 1987 Oct;56(4):401-5 PMID: 2825748
  4. Chemosensitivity testing of human lung cancer cell lines using the MTT assay.
    Br J Cancer. 1988 Jun;57(6):540-7 PMID: 2841961
  5. Mapping of the human retinoic acid receptor to the q21 band of chromosome 17.
    Hum Genet. 1988 Oct;80(2):186-8 PMID: 2844649
  6. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22.
    Proc Natl Acad Sci U S A. 1988 Oct;85(19):7177-81 PMID: 2845399
  7. Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins.
    J Biol Chem. 1988 Nov 25;263(33):17724-9 PMID: 2846576
  8. A subthreshold level of DNA topoisomerases leads to the excision of yeast rDNA as extrachromosomal rings.
    Cell. 1989 Jun 16;57(6):975-85 PMID: 2544296
  9. Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay.
    Cancer Res. 1989 Aug 15;49(16):4435-40 PMID: 2743332
  10. DNA topoisomerase poisons as antitumor drugs.
    Annu Rev Biochem. 1989;58:351-75 PMID: 2549853
  11. Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes.
    Proc Natl Acad Sci U S A. 1989 Dec;86(23):9431-5 PMID: 2556712
  12. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II.
    Biochemistry. 1989 Oct 3;28(20):8154-60 PMID: 2557897
  13. Differences between normal and ras-transformed NIH-3T3 cells in expression of the 170kD and 180kD forms of topoisomerase II.
    Cancer Res. 1990 May 15;50(10):2901-8 PMID: 2159365
  14. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells.
    Cell Growth Differ. 1991 Apr;2(4):209-14 PMID: 1651102
  15. Topoisomerase II alpha and topoisomerase II beta genes: characterization and mapping to human chromosomes 17 and 3, respectively.
    Cancer Res. 1992 Jan 1;52(1):231-4 PMID: 1309226
  16. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression.
    Cancer Res. 1992 Apr 1;52(7):1666-74 PMID: 1312895
  17. Amplification of the topoisomerase II alpha gene in a non-small cell lung cancer cell line and characterisation of polymorphisms at the human topoisomerase II alpha and beta loci in normal tissue.
    Genes Chromosomes Cancer. 1992 Mar;4(2):169-75 PMID: 1373318
  18. Monoclonal antibodies to human DNA topoisomerase I and the two isoforms of DNA topoisomerase II: 170- and 180-kDa isozymes.
    Exp Cell Res. 1992 Jun;200(2):452-9 PMID: 1315288
  19. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization.
    Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5321-5 PMID: 1351679
  20. Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II.
    Cancer Res. 1992 Aug 15;52(16):4467-72 PMID: 1322791
  21. Retinoids in cancer prevention and therapy.
    Ann Oncol. 1992 Jul;3(7):513-26 PMID: 1498071
  22. The distribution of immunoreactive topoisomerase II Protein in human tissues and neoplasms.
    Oncol Res. 1992;4(4-5):157-66 PMID: 1324031
  23. Cloning and characterization of the 5'-flanking region of the human topoisomerase II alpha gene.
    J Biol Chem. 1992 Sep 15;267(26):18961-5 PMID: 1382064
  24. DNA topoisomerase-targeting antitumor agents and drug resistance.
    Anticancer Drugs. 1992 Aug;3(4):323-30 PMID: 1330080
  25. DNA topoisomerase II: a review of its involvement in chromosome structure, DNA replication, transcription and mitosis.
    Cell Biol Int Rep. 1992 Aug;16(8):717-24 PMID: 1332830
  26. Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24.
    Nucleic Acids Res. 1992 Nov 11;20(21):5587-92 PMID: 1333583
  27. The complete primary structure of protein kinase C--the major phorbol ester receptor.
    Science. 1986 Aug 22;233(4766):853-9 PMID: 3755547
  28. Retinoic acid in acute promyelocytic leukemia: the promise and the paradox.
    Cancer Cells. 1991 Jun;3(6):211-20 PMID: 1911035
  29. High frequency of retinoic acid receptor beta abnormalities in human lung cancer.
    Oncogene. 1991 Oct;6(10):1859-68 PMID: 1717924
  30. Quantification of inter- and intra-nuclear variation of fluorescence in situ hybridization signals.
    Cytometry. 1992;13(8):831-8 PMID: 1459000
Article Info
Journal
British journal of cancer
Abbr.
Br J Cancer
ISSN
0007-0920
DOI
10.1038/bjc.1993.430
Published
1993-10-00
Pages
793-800
Language
English
Region
England
NLM ID
0370635
PMCID
PMC1968606
Subset
IM
External Links
PubMed source DOI: 10.1038/bjc.1993.430 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2